Lyon, France

Marc Billaud

This inventor holds 1 USPTO granted patent. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Billaud. Retrieved from https://idiyas.com/inventor/marc-billaud-bbhywnwt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Marc Billaud

Introduction

Marc Billaud is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on mitochondrial activity inhibitors that target tumoral metabolism, showcasing his commitment to advancing medical science.

Latest Patents

Marc Billaud holds a patent for "Mitochondrial activity inhibitors targeting tumoral metabolism." This invention relates to compounds of formula (I), wherein specific groups and atoms are utilized to create effective treatments for cancer. The compounds are designed to inhibit mitochondrial activity in tumor cells, potentially leading to improved therapeutic outcomes for patients.

Career Highlights

Throughout his career, Marc Billaud has worked with prestigious institutions such as the Centre Léon Bérard and the Centre National de la Recherche Scientifique (CNRS). His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Marc has collaborated with esteemed colleagues, including Renaud Prudent and Martine Cordier-Bussat. These partnerships have enriched his research and expanded the impact of his inventions in the scientific community.

Conclusion

Marc Billaud's innovative work in developing mitochondrial activity inhibitors represents a significant advancement in cancer treatment. His dedication to research and collaboration with other experts highlights the importance of teamwork in achieving scientific breakthroughs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…